Summary
SARS-CoV-2 variants of concern (VOCs) arise against the backdrop of increasingly heterogeneous human connectivity and population immunity. Through a large-scale phylodynamic analysis of 115,622 Omicron genomes, we identified >6,000 independent introductions of the antigenically distinct virus into England and reconstructed the dispersal history of resulting local transmission. Travel restrictions on southern Africa did not reduce BA.1 importation intensity as secondary hubs became major exporters. We explored potential drivers of BA.1 spread across England and discovered an early period during which viral lineage movements mainly occurred between larger cities, followed by a multi-focal spatial expansion shaped by shorter distance mobility patterns. We also found evidence that disease incidence impacted human commuting behaviours around major travel hubs. Our results offer a detailed characterisation of processes that drive the invasion of an emerging VOC across multiple spatial scales and provide unique insights on the interplay between disease spread and human mobility.
Highlights
Over 6,000 introductions ignited the epidemic wave of Omicron BA.1 in England
Importations prior to international travel restrictions were responsible for majority of local BA.1 infections but importations continued from sources other than southern Africa
Human mobility at regional and local spatial scales shaped dissemination and growth of BA.1
Changes in human commuting patterns are associated with higher case incidence in travel hubs across England
Competing Interest Statement
K.K. is the founder of BlueDot, a social enterprise that develops digital technologies for public health. M.D. is employed at BlueDot. L.L. and N.W. are employed by Google and own equity in Alphabet. All other authors declare no competing interests.
Funding Statement
COG-UK is supported by funding from the Medical Research Council (MRC) part of UK Research & Innovation (UKRI), the National Institute of Health Research (NIHR) [grant code: MC_PC_19027], and Genome Research Limited, operating as the Wellcome Sanger Institute. The authors acknowledge use of data generated through the COVID-19 Genomics Programme funded by the Department of Health and Social Care. MUGK acknowledges funding from The Rockefeller Foundation, Google.org, the Oxford Martin School Pandemic Genomics programme (also O.G.P. and A.E.Z.), European Union Horizon 2020 project MOOD (#874850) (also supports R.I., S.D. and P.L.), The John Fell Fund, and a Branco Weiss Fellowship. This work was also supported by the Foreign, Commonwealth & Development Office and Wellcome [225288/Z/22/Z] and [226052/Z/22/Z] (to M.U.G.K.). V.H. was supported by the Biotechnology and Biological Sciences Research Council (BBSRC) [grant number BB/M010996/1]. J.T.M, R.C. and A.R. acknowledge support from the Wellcome Trust [Collaborators Award 206298/Z/17/Z - ARTIC network]. SD also acknowledges support from the Fonds National de la Recherche Scientifique (F.R.S.-FNRS, Belgium; grant F.4515.22) and from the Research Foundation - Flanders (Fonds voor Wetenschappelijk Onderzoek - Vlaanderen, FWO, Belgium; grant G098321N). A.R. is also supported by the European Research Council [grant agreement number 725422 - ReservoirDOCS] and Bill & Melinda Gates Foundation [OPP1175094 - HIV-PANGEA II]. SB is supported by the Clarendon Scholarship, University of Oxford and NERC DTP [grant number NE/S007474/1].]. M.A.S. acknowledges support from US National Institutes of Health grants R01 AI153044 and R01 AI162611. M.A.S. and X.J. gratefully acknowledge support from NVIDIA Corporation and Advanced Micro Devices, Inc. with the donation of parallel computing resources used for this research. SC acknowledges Labex IBEID (grant ANR-10-LABX-62-IBEID), European Union Horizon 2020 projects VEO (874735) and RECOVER (101003589), AXARF, Groupama, EMERGEN (ANRS0151) and INCEPTION (PIA/ANR-16-CONV-0005). E.W., H.T. and T.dO are supported in part by grants from the Rockefeller Foundation (HTH 017), the Abbott Pandemic Defense Coalition (APDC), the African Society for Laboratory Medicine, the National Institute of Health USA (U01 AI151698) for the United World Antivirus Research Network (UWARN) and the INFORM Africa project through IHVN (U54 TW012041). The views expressed are those of the author and not necessarily those of the Department of Health and Social Care, UKHSA, or European commission or any of the other funders.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was conducted as part of surveillance for COVID-19 infections under the auspices of Section 251 of the NHS Act 2006 and/or Regulation 3 of The Health Service (Control of Patient Information) Regulations 2002. They therefore did not require individual patient consent or ethical approval. Public Health England affiliated authors had access to identifiable patient data. Other authors only had access to anonymised or summerised data. The COG-UK study protocol was approved by the Public Health England Research Ethics Governance Group (reference: R&D NR0195).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵⇑ Consortium members and affiliations are listed in the Supplementary Information.
Data Availability
UK genome sequences used were generated by the COVID-19 Genomics UK consortium (COG-UK, https://www.cogconsortium.uk/). Data linking COG-IDs to location have been removed to protect privacy, however if you require this data please visit https://www.cogconsortium.uk/contact/ for information on accessing consortium-only data. The Google COVID-19 Aggregated Mobility Research Dataset used for this study is available with permission from Google LLC. Code to reproduce the analyses will be made available on our GitHub repository before publication.
